Related Experiment Video
Updated: May 11, 2026
05:42
Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
Published on: January 7, 2019
Modified Atkins diet vs classic ketogenic formula in intractable epilepsy
O F El-Rashidy1, M F Nassar, I A Abdel-Hamid
1Pediatric Neurology Department, Children's Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Acta Neurologica Scandinavica
|May 18, 2013
Summary
The ketogenic diet (KD), including classic 4:1 formula and modified Atkins diet (MAD), is a safe and effective treatment for childhood epilepsy. The liquid KD formula showed superior seizure control and growth benefits.
Area of Science:
- Neurology
- Pediatrics
- Metabolic Disorders
Background:
- Intractable childhood epilepsy poses significant management challenges.
- Dietary therapies like the ketogenic diet (KD) are explored for refractory cases.
- The classic 4:1 formula and modified Atkins diet (MAD) are common KD variations.
Purpose of the Study:
- To assess the efficacy, safety, and tolerability of KD (classic 4:1 and MAD) in children with intractable epilepsy.
- To compare the effects of different KD formulations and standard care on seizure control and growth.
- To evaluate the impact of KD on serum lipid profiles.
Main Methods:
- A study involving 40 pediatric patients with symptomatic intractable epilepsy.
- Participants were assigned to modified Atkins diet (MAD), classic 4:1 ketogenic liquid formula, or a control group.
- Anthropometric measurements and serum lipid profiles were monitored over 6 months.
Main Results:
- The liquid ketogenic formula group exhibited a significantly higher body mass index after 6 months.
- Serum lipid profiles remained within normal age- and sex-specific limits for KD patients.
- Both KD groups showed seizure improvement, with the liquid formula group demonstrating the best outcomes.
Conclusions:
- Ketogenic diets (KD), including classic 4:1 and MAD, are tolerable, safe, and effective adjuvant therapies for intractable childhood epilepsy.
- Limited adverse effects on growth and acceptable lipid profile changes were observed.
- Liquid ketogenic formula offered enhanced growth patterns and superior seizure control compared to MAD and standard care.
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
01:25Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...